Clinical Trial Update: Iressa Follow-up Trial [Phase 3]

View source ↗

Summary

Phase 3 follow-up trial of Iressa (gefitinib) in non-small cell lung cancer and breast cancer has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer, Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-06-23